On the public citation graph

Drug repositioning for Alzheimer's disease

0 signed · 431 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/archinte.162.18.2046openalex-snapshot
The Prevention of Dementia With Antihypertensive Treatment New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study
inferredcites →https://doi.org/10.1001/archneur.63.5.noc60013openalex-snapshot
Antihypertensive Medication Use and Incident Alzheimer Disease
inferredcites →https://doi.org/10.1001/archneurol.2010.225openalex-snapshot
Insulin Resistance and Alzheimer-like Reductions in Regional Cerebral Glucose Metabolism for Cognitively Normal Adults With Prediabetes or Early Type 2 Diabetes
inferredcites →https://doi.org/10.1001/archneurol.2011.233openalex-snapshot
Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment
inferredcites →https://doi.org/10.1001/jama.1997.03540340047031openalex-snapshot
Brain Infarction and the Clinical Expression of Alzheimer Disease The Nun Study
inferredcites →https://doi.org/10.1001/jama.2009.1866openalex-snapshot
Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease A Randomized Controlled Trial
inferredcites →https://doi.org/10.1001/jama.277.10.813openalex-snapshot
Brain infarction and the clinical expression of Alzheimer disease. The Nun Study
inferredcites →https://doi.org/10.1002/14651858.cd000147openalex-snapshot
Nimodipine for primary degenerative, mixed and vascular dementia
inferredcites →https://doi.org/10.1002/14651858.cd004034.pub3openalex-snapshot
Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia
inferredcites →https://doi.org/10.1002/14651858.cd006378.pub2openalex-snapshot
Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease
inferredcites →https://doi.org/10.1002/14651858.cd007204.pub2openalex-snapshot
Cannabinoids for the treatment of dementia
inferredcites →https://doi.org/10.1002/glia.20051openalex-snapshot
Minocycline inhibits neuronal death and glial activation induced by β‐amyloid peptide in rat hippocampus
inferredcites →https://doi.org/10.1002/glia.20338openalex-snapshot
Minocycline affects microglia activation, Aβ deposition, and behavior in APP‐tg mice
inferredcites →https://doi.org/10.1002/glia.20726openalex-snapshot
Minocycline reduces engraftment and activation of bone marrow‐derived cells but sustains their phagocytic activity in a mouse model of Alzheimer's disease
inferredcites →https://doi.org/10.1002/gps.1964openalex-snapshot
A feasibility and tolerability study of lithium in Alzheimer's disease
inferredcites →https://doi.org/10.1002/gps.2089openalex-snapshot
A profile of impaired insulin degradation in relation to late‐life cognitive decline: A preliminary investigation
inferredcites →https://doi.org/10.1002/gps.2638openalex-snapshot
Demonstration of safety in Alzheimer's patients for intervention with an anti‐hypertensive drug Nilvadipine: results from a 6‐week open label study
inferredcites →https://doi.org/10.1002/gps.2735openalex-snapshot
Apolipoprotein E genotype‐specific short‐term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients—an open‐label trial
inferredcites →https://doi.org/10.1002/jnr.10611openalex-snapshot
Glucagon‐like peptide‐1 decreases endogenous amyloid‐β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron
inferredcites →https://doi.org/10.1002/jnr.22565openalex-snapshot
Novel GLP‐1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain
inferredcites →https://doi.org/10.1002/mds.20018openalex-snapshot
Minocycline in Huntington's disease: A pilot study
inferredcites →https://doi.org/10.1002/mds.23236openalex-snapshot
A futility study of minocycline in Huntington's disease
inferredcites →https://doi.org/10.1002/msj.20155openalex-snapshot
Role of Vascular Risk Factors and Vascular Dysfunction in Alzheimer's Disease
inferredcites →https://doi.org/10.1002/path.2449openalex-snapshot
Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques
inferredcites →https://doi.org/10.1007/s00213-008-1101-3openalex-snapshot
An extract of Salvia (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers
inferredcites →https://doi.org/10.1016/b978-0-12-381517-0.00013-8openalex-snapshot
The Role of GLP-1 in Neuronal Activity and Neurodegeneration
inferredcites →https://doi.org/10.1016/j.amjhyper.2005.02.013openalex-snapshot
Effect of Baseline Cognitive Function and Antihypertensive Treatment on Cognitive and Cardiovascular Outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE)
inferredcites →https://doi.org/10.1016/j.bbrc.2008.08.032openalex-snapshot
Telmisartan prevented cognitive decline partly due to PPAR-γ activation
inferredcites →https://doi.org/10.1016/j.brainresrev.2007.09.001openalex-snapshot
Common pathological processes in Alzheimer disease and type 2 diabetes: A review
inferredcites →https://doi.org/10.1016/j.cell.2010.06.036openalex-snapshot
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
inferredcites →https://doi.org/10.1016/j.ejphar.2004.02.045openalex-snapshot
Insulin and the insulin receptor in experimental models of learning and memory
inferredcites →https://doi.org/10.1016/j.ejphar.2004.02.047openalex-snapshot
Insulin-like growth factor-I, cognition and brain aging
inferredcites →https://doi.org/10.1016/j.ejphar.2004.02.048openalex-snapshot
Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease
inferredcites →https://doi.org/10.1016/j.ejphar.2004.02.049openalex-snapshot
Glucose metabolism and insulin receptor signal transduction in Alzheimer disease
inferredcites →https://doi.org/10.1016/j.ejphar.2004.02.050openalex-snapshot
The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease
inferredcites →https://doi.org/10.1016/j.ejphar.2011.03.048openalex-snapshot
Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood–brain barrier
inferredcites →https://doi.org/10.1016/j.ejphar.2011.11.005openalex-snapshot
(Val8) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains
inferredcites →https://doi.org/10.1016/j.jbspin.2010.01.017openalex-snapshot
Improvement of cognition, a potential benefit of anti-TNF therapy in elderly patients with rheumatoid arthritis
inferredcites →https://doi.org/10.1016/j.jep.2006.12.015openalex-snapshot
Protective effects of ginsenoside Rg2 against glutamate-induced neurotoxicity in PC12 cells
inferredcites →https://doi.org/10.1016/j.nbd.2006.01.008openalex-snapshot
Retinoic acid normalizes nuclear receptor mediated hypo-expression of proteins involved in β-amyloid deposits in the cerebral cortex of vitamin A deprived rats
inferredcites →https://doi.org/10.1016/j.nbd.2007.01.004openalex-snapshot
Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid β-protein metabolism in mouse models of Alzheimer disease
inferredcites →https://doi.org/10.1016/j.nbd.2010.08.020openalex-snapshot
L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease
inferredcites →https://doi.org/10.1016/j.neurobiolaging.2008.04.002openalex-snapshot
Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling
inferredcites →https://doi.org/10.1016/j.neurobiolaging.2009.10.009openalex-snapshot
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
inferredcites →https://doi.org/10.1016/j.neurobiolaging.2010.02.014openalex-snapshot
Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice
inferredcites →https://doi.org/10.1016/j.neuropharm.2011.01.033openalex-snapshot
Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s-like changes
inferredcites →https://doi.org/10.1016/j.neuroscience.2010.08.028openalex-snapshot
Val8-glucagon-like peptide-1 protects against Aβ1–40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats
inferredcites →https://doi.org/10.1016/j.physbeh.2004.07.022openalex-snapshot
Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans
inferredcites →https://doi.org/10.1016/j.pneurobio.2011.07.001openalex-snapshot
Brain renin-angiotensin—A new look at an old system
inferredcites →https://doi.org/10.1016/j.regpep.2010.07.102openalex-snapshot
The novel GLP-1 analogue liraglutide has neuroprotective properties in a mouse model of Alzheimer's disease
inferredcites →https://doi.org/10.1016/j.tins.2009.07.006openalex-snapshot
Angiotensins in Alzheimer's disease – friend or foe?
inferredcites →https://doi.org/10.1016/j.ydbio.2006.06.027openalex-snapshot
Interactions between retinoic acid, nerve growth factor and sonic hedgehog signalling pathways in neurite outgrowth
inferredcites →https://doi.org/10.1016/j.ydbio.2008.11.018openalex-snapshot
Sequential RARβ and α signalling in vivo can induce adult forebrain neural progenitor cells to differentiate into neurons through Shh and FGF signalling pathways
inferredcites →https://doi.org/10.1016/s0014-5793(00)02380-2openalex-snapshot
Anti‐amyloidogenic activity of tetracyclines: studies in vitro
inferredcites →https://doi.org/10.1016/s0022-3956(02)00085-7openalex-snapshot
Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine
inferredcites →https://doi.org/10.1016/s0090-9556(25)08301-1openalex-snapshot
Kinetics of tissue distribution and elimination of retinoid drugs in the rat. I. Acitretin.
inferredcites →https://doi.org/10.1016/s0140-6736(08)61075-2openalex-snapshot
Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
inferredcites →https://doi.org/10.1016/s0140-6736(09)61375-1openalex-snapshot
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
inferredcites →https://doi.org/10.1016/s0140-6736(10)61349-9openalex-snapshot
Alzheimer's disease
inferredcites →https://doi.org/10.1016/s0140-6736(96)90608-xopenalex-snapshot
15-year longitudinal study of blood pressure and dementia
inferredcites →https://doi.org/10.1016/s0197-4580(00)00096-8openalex-snapshot
Midlife blood pressure and dementia: the Honolulu–Asia aging study☆
inferredcites →https://doi.org/10.1016/s1474-4422(05)70141-1openalex-snapshot
The age-dependent relation of blood pressure to cognitive function and dementia
inferredcites →https://doi.org/10.1016/s1474-4422(07)70178-3openalex-snapshot
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
inferredcites →https://doi.org/10.1016/s1474-4422(07)70270-3openalex-snapshot
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
inferredcites →https://doi.org/10.1016/s1474-4422(08)70090-5openalex-snapshot
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial
inferredcites →https://doi.org/10.1016/s1474-4422(10)70119-8openalex-snapshot
Alzheimer's disease: clinical trials and drug development
inferredcites →https://doi.org/10.1016/s1474-4422(10)70250-7openalex-snapshot
Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies
inferredcites →https://doi.org/10.1016/s1734-1140(11)70504-7openalex-snapshot
Increases in β-amyloid protein in the hippocampus caused by diabetic metabolic disorder are blocked by minocycline through inhibition of NF-κB pathway activation
inferredcites →https://doi.org/10.1038/22124openalex-snapshot
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
inferredcites →https://doi.org/10.1038/nrd1468openalex-snapshot
Drug repositioning: identifying and developing new uses for existing drugs
inferredcites →https://doi.org/10.1038/nrd2959openalex-snapshot
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
inferredcites →https://doi.org/10.1038/nrd3505openalex-snapshot
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
inferredcites →https://doi.org/10.1038/sj.embor.7400784openalex-snapshot
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
inferredcites →https://doi.org/10.1038/sj.ijo.0802206openalex-snapshot
Entry of exendin-4 into brain is rapid but may be limited at high doses
inferredcites →https://doi.org/10.1038/sj.jhh.1001442openalex-snapshot
The renin-angiotensin system in the brain: possible therapeutic implications for AT1-receptor blockers
inferredcites →https://doi.org/10.1073/pnas.0437937100openalex-snapshot
Evidence for defective retinoid transport and function in late onset Alzheimer's disease
inferredcites →https://doi.org/10.1073/pnas.0813404106openalex-snapshot
Intracerebroventricular amyloid-β antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice
inferredcites →https://doi.org/10.1089/rej.2009.0944openalex-snapshot
Protective Effects of Intranasal Losartan in the APP/PS1 Transgenic Mouse Model of Alzheimer Disease
inferredcites →https://doi.org/10.1093/bja/65.4.514openalex-snapshot
EFFECTS OF NIMODIPINE ON CEREBRAL BLOOD FLOW AND NEUROPSYCHOLOGICAL OUTCOME AFTER CARDIAC SURGERY
inferredcites →https://doi.org/10.1096/fj.07-9574lsfopenalex-snapshot
Dose translation from animal to human studies revisited
inferredcites →https://doi.org/10.1096/fj.08-121392openalex-snapshot
Up‐regulation of the α‐secretase ADAM10 by retinoic acid receptors and acitretin
inferredcites →https://doi.org/10.1097/00004850-200411000-00004openalex-snapshot
Neuroprotection in Huntington??s disease: a 2-year study on minocycline
inferredcites →https://doi.org/10.1097/00004872-200305000-00011openalex-snapshot
The Study on Cognition and Prognosis in the Elderly (SCOPE)
inferredcites →https://doi.org/10.1097/mnm.0b013e32804c58aaopenalex-snapshot
Favourable effects of nilvadipine on cognitive function and regional cerebral blood flow on SPECT in hypertensive patients with mild cognitive impairment
inferredcites →https://doi.org/10.1097/wnf.0b013e3181342f32openalex-snapshot
A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease
inferredcites →https://doi.org/10.1111/j.1460-9568.2004.03563.xopenalex-snapshot
Disruption of the retinoid signalling pathway causes a deposition of amyloid β in the adult rat brain
inferredcites →https://doi.org/10.1111/j.1460-9568.2010.07426.xopenalex-snapshot
Retinoic acid receptor‐α signalling antagonizes both intracellular and extracellular amyloid‐β production and prevents neuronal cell death caused by amyloid‐β
inferredcites →https://doi.org/10.1111/j.1471-4159.2009.06096.xopenalex-snapshot
Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice
inferredcites →https://doi.org/10.1111/j.1530-0277.2007.00450.xopenalex-snapshot
Insulin and Insulin‐Like Growth Factor Resistance With Neurodegeneration in an Adult Chronic Ethanol Exposure Model
inferredcites →https://doi.org/10.1111/j.1532-5415.2004.52109.xopenalex-snapshot
A Randomized, Controlled Trial of Doxycycline and Rifampin for Patients with Alzheimer's Disease
inferredcites →https://doi.org/10.1111/j.1749-6632.2010.05726.xopenalex-snapshot
Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials
inferredcites →https://doi.org/10.1124/jpet.300.3.958openalex-snapshot
A Novel Neurotrophic Property of Glucagon-Like Peptide 1: A Promoter of Nerve Growth Factor-Mediated Differentiation in PC12 Cells
inferredcites →https://doi.org/10.1126/science.1217697openalex-snapshot
ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
inferredcites →https://doi.org/10.1126/scitranslmed.3001318openalex-snapshot
Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data
inferredcites →https://doi.org/10.1126/scitranslmed.3002156openalex-snapshot
Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance
inferredcites →https://doi.org/10.1136/bmj.b5465openalex-snapshot
Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis
inferredcites →https://doi.org/10.1159/000285514openalex-snapshot
Early-Stage Inflammation and Experimental Therapy in Transgenic Models of the Alzheimer-Like Amyloid Pathology
inferredcites →https://doi.org/10.1159/000318845openalex-snapshot
Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study
inferredcites →https://doi.org/10.1159/000337230openalex-snapshot
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
inferredcites →https://doi.org/10.1161/hypertensionaha.109.138586openalex-snapshot
Angiotensin Receptor Blocker Prevented β-Amyloid-Induced Cognitive Impairment Associated With Recovery of Neurovascular Coupling
inferredcites →https://doi.org/10.1172/jci31547openalex-snapshot
Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease
inferredcites →https://doi.org/10.1212/01.wnl.0000049936.85487.7aopenalex-snapshot
Minocycline for Huntington’s disease: An open label study
inferredcites →https://doi.org/10.1212/01.wnl.0000265401.62434.36openalex-snapshot
Intranasal insulin improves cognition and modulates β-amyloid in early AD
inferredcites →https://doi.org/10.1212/wnl.0b013e3181b6bb95openalex-snapshot
Systemic inflammation and disease progression in Alzheimer disease
inferredcites →https://doi.org/10.1212/wnl.0b013e3181c67808openalex-snapshot
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
inferredcites →https://doi.org/10.1212/wnl.0b013e3181ffe4f6openalex-snapshot
Insulin metabolism and the risk of Alzheimer disease
inferredcites →https://doi.org/10.1212/wnl.0b013e318230a16copenalex-snapshot
Chronic divalproex sodium use and brain atrophy in Alzheimer disease
inferredcites →https://doi.org/10.1212/wnl.0b013e31824e8f0dopenalex-snapshot
Amantadine
inferredcites →https://doi.org/10.1212/wnl.45.6.1161openalex-snapshot
Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population
inferredcites →https://doi.org/10.1212/wnl.58.8.1175openalex-snapshot
The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function
inferredcites →https://doi.org/10.1242/dmm.006841openalex-snapshot
A translational continuum of model systems for evaluating treatment strategies in Alzheimer’s disease: isradipine as a candidate drug
inferredcites →https://doi.org/10.1248/bpb.30.698openalex-snapshot
Nilvadipine Prevents the Impairment of Spatial Memory Induced by Cerebral Ischemia Combined with .BETA.-Amyloid in Rats
inferredcites →https://doi.org/10.1248/bpb.32.1307openalex-snapshot
Oral Administration of Synthetic Retinoid Am80 (Tamibarotene) Decreases Brain .BETA.-Amyloid Peptides in APP23 Mice
inferredcites →https://doi.org/10.1371/journal.pone.0012244openalex-snapshot
Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial
inferredcites →https://doi.org/10.1385/jmn:18:1-2:07openalex-snapshot
Interactions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
inferredcites →https://doi.org/10.1515/revneuro.2005.16.3.181openalex-snapshot
Development of Beta-Amyloid-induced Neurodegeneration in Alzheimer's Disease and Novel Neuroprotective Strategies
inferredcites →https://doi.org/10.1517/17460441.2012.645534openalex-snapshot
Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease
inferredcites →https://doi.org/10.1523/jneurosci.0529-11.2011openalex-snapshot
The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease
inferredcites →https://doi.org/10.1523/jneurosci.3153-08.2008openalex-snapshot
Retinoic Acid Attenuates β-Amyloid Deposition and Rescues Memory Deficits in an Alzheimer's Disease Transgenic Mouse Model
inferredcites →https://doi.org/10.1523/jneurosci.4371-06.2007openalex-snapshot
Minocycline Reduces Microglial Activation and Improves Behavioral Deficits in a Transgenic Model of Cerebral Microvascular Amyloid
inferredcites →https://doi.org/10.1586/ern.09.86openalex-snapshot
All-transretinoic acid as a novel therapeutic strategy for Alzheimer’s disease
inferredcites →https://doi.org/10.1586/ern.11.13openalex-snapshot
Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer’s disease
inferredcites →https://doi.org/10.2119/molmed.2010.00180openalex-snapshot
Selective Antihypertensive Dihydropyridines Lower Aβ Accumulation by Targeting both the Production and the Clearance of Aβ across the Blood-Brain Barrier
inferredcites →https://doi.org/10.2165/00044011-199611040-00001openalex-snapshot
Nimodipine in the Treatment of Probable Alzheimerʼs Disease
inferredcites →https://doi.org/10.2174/156720509788486581openalex-snapshot
Towards Retinoid Therapy for Alzheimers Disease
inferredcites →https://doi.org/10.2337/db07-0171openalex-snapshot
Alzheimer-Like Changes in Rat Models of Spontaneous Diabetes
inferredcites →https://doi.org/10.3233/jad-2008-13309openalex-snapshot
Intranasal Insulin Administration Dose-Dependently Modulates Verbal Memory and Plasma Amyloid-β in Memory-Impaired Older Adults
inferredcites →https://doi.org/10.3233/jad-2008-13405openalex-snapshot
Herpes Simplex Virus Type 1 in Alzheimer's Disease: The Enemy Within
inferredcites →https://doi.org/10.3233/jad-2009-0925openalex-snapshot
Identification of Antihypertensive Drugs Which Inhibit Amyloid-β Protein Oligomerization
inferredcites →https://doi.org/10.3233/jad-2010-100174openalex-snapshot
Dimebon (Latrepirdine) Enhances Mitochondrial Function and Protects Neuronal Cells from Death
inferredcites →https://doi.org/10.3233/jad-2010-100204openalex-snapshot
Reductions in Amyloid-β-Derived Neuroinflammation, with Minocycline, Restore Cognition but do not Significantly Affect Tau Hyperphosphorylation
inferredcites →https://doi.org/10.3233/jad-2011-101524openalex-snapshot
Incidence of Dementia is Increased in Type 2 Diabetes and Reduced by the Use of Sulfonylureas and Metformin
inferredcites →https://doi.org/10.3233/jad-2011-110347openalex-snapshot
Associations of Anti-Hypertensive Treatments with Alzheimer's Disease, Vascular Dementia, and Other Dementias
inferredcites →https://doi.org/10.3233/jad-2012-111376openalex-snapshot
The Renin-Angiotensin System and Antihypertensive Drugs in Alzheimer's Disease: Current Standing of the Angiotensin Hypothesis?
inferredcites →https://doi.org/10.4088/jcp.08m04606openalex-snapshot
Lithium Trial in Alzheimer's Disease
inferredcites →https://doi.org/10.4161/pri.3.2.8820openalex-snapshot
Minocycline as a potential therapeutic agent in neurodegenerative disorders characterized by protein misfolding

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.1001/jamaneurol.2019.3762openalex-snapshot
Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease
inferred← citeshttps://doi.org/10.1001/jamaneurol.2019.3784openalex-snapshot
Pragmatic Trials and Repurposed Drugs for Alzheimer Disease
inferred← citeshttps://doi.org/10.1002/0471250953.bi0808s45openalex-snapshot
Using VisANT to Analyze Networks
inferred← citeshttps://doi.org/10.1002/9781118352335.appopenalex-snapshot
Recommended Further Reading
inferred← citeshttps://doi.org/10.1002/9781118788523.ch4openalex-snapshot
Species Differences and Impact of Disease State on BBB
inferred← citeshttps://doi.org/10.1002/alz.13349openalex-snapshot
Dementia risk in patients with type 2 diabetes: Comparing metformin with no pharmacological treatment
inferred← citeshttps://doi.org/10.1002/alz.70503openalex-snapshot
Bisphosphonates and the risk of dementia in patients with osteoporosis or fragility fracture: A population‐based study in Hong Kong
inferred← citeshttps://doi.org/10.1002/alz.71495openalex-snapshot
Repurposed drug prioritization pipeline for a multi‐arm platform trial in clinical Alzheimer's disease
inferred← citeshttps://doi.org/10.1002/ana.25642openalex-snapshot
Lipid lowering and Alzheimer disease risk: A mendelian randomization study
inferred← citeshttps://doi.org/10.1002/ange.201501515openalex-snapshot
Neuritogenic Militarinone‐Inspired 4‐Hydroxypyridones Target the Stress Pathway Kinase MAP4K4
inferred← citeshttps://doi.org/10.1002/ange.202420547openalex-snapshot
A Self‐Reinforced “Microglia Energy Modulator” for Synergistic Amyloid‐β Clearance in Alzheimer's Disease Model
inferred← citeshttps://doi.org/10.1002/anie.201501515openalex-snapshot
Neuritogenic Militarinone‐Inspired 4‐Hydroxypyridones Target the Stress Pathway Kinase MAP4K4
inferred← citeshttps://doi.org/10.1002/anie.202420547openalex-snapshot
A Self‐Reinforced “Microglia Energy Modulator” for Synergistic Amyloid‐β Clearance in Alzheimer's Disease Model
inferred← citeshttps://doi.org/10.1002/chem.201805835openalex-snapshot
Metal–Organic Frameworks Harness Cu Chelating and Photooxidation Against Amyloid β Aggregation in Vivo
inferred← citeshttps://doi.org/10.1002/cmdc.201500123openalex-snapshot
Target Fishing by Cross‐Docking to Explain Polypharmacological Effects
inferred← citeshttps://doi.org/10.1002/cmdc.201700456openalex-snapshot
Minor Structural Variations of Small Molecules Tune Regulatory Activities toward Pathological Factors in Alzheimer's Disease
inferred← citeshttps://doi.org/10.1002/cmdc.202100428openalex-snapshot
Formaldehyde‐Crosslinked Nontoxic Aβ Monomers to Form Toxic Aβ Dimers and Aggregates: Pathogenicity and Therapeutic Perspectives
inferred← citeshttps://doi.org/10.1002/glia.22992openalex-snapshot
KCa3.1—a microglial target ready for drug repurposing?
inferred← citeshttps://doi.org/10.1002/gps.3958openalex-snapshot
Patient and carer views on participating in clinical trials for prodromal Alzheimer's disease and mild cognitive impairment
inferred← citeshttps://doi.org/10.1002/jnr.23315openalex-snapshot
Mildronate improves cognition and reduces amyloid‐β pathology in transgenic Alzheimer's disease mice
inferred← citeshttps://doi.org/10.1002/med.21434openalex-snapshot
Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends
inferred← citeshttps://doi.org/10.1002/med.21709openalex-snapshot
Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing
inferred← citeshttps://doi.org/10.1002/med.21719openalex-snapshot
A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy
inferred← citeshttps://doi.org/10.1002/trc2.12050openalex-snapshot
Alzheimer's disease drug development pipeline: 2020
inferred← citeshttps://doi.org/10.1002/trc2.12268openalex-snapshot
Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers
inferred← citeshttps://doi.org/10.1007/978-1-4939-2627-5_1openalex-snapshot
Alzheimer’s as a Systems-Level Disease Involving the Interplay of Multiple Cellular Networks
inferred← citeshttps://doi.org/10.1007/978-3-031-04998-9_13openalex-snapshot
Polypharmacology in Old Drug Rediscovery: Drug Repurposing
inferred← citeshttps://doi.org/10.1007/978-3-031-46545-1_20openalex-snapshot
In Silico Design of Acetylcholinesterase and Glycogen Synthase Kinase-3β Multi-target Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-319-42291-6_31openalex-snapshot
Using the Ranking-Based KNN Approach for Drug Repositioning Based on Multiple Information
inferred← citeshttps://doi.org/10.1007/978-981-19-7376-5_2openalex-snapshot
Microbiota–Gut–Brain Axis: Pathophysiological Mechanism in Neuropsychiatric Disorders
inferred← citeshttps://doi.org/10.1007/978-981-95-4522-3_12openalex-snapshot
Drug Repurposing for Neurological Disorders
inferred← citeshttps://doi.org/10.1007/978-981-97-5016-0_7openalex-snapshot
Drug Repurposing in CNS Disorders
inferred← citeshttps://doi.org/10.1007/s10571-025-01630-5openalex-snapshot
Comprehensive and In-Depth Molecular and Pathway Studies of the Hippocampus in Alzheimer’s Disease
inferred← citeshttps://doi.org/10.1007/s11033-021-06512-9openalex-snapshot
Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease
inferred← citeshttps://doi.org/10.1007/s11095-015-1665-7openalex-snapshot
Identification of Nitazoxanide as a Group I Metabotropic Glutamate Receptor Negative Modulator for the Treatment of Neuropathic Pain: An In Silico Drug Repositioning Study
inferred← citeshttps://doi.org/10.1007/s12031-016-0857-xopenalex-snapshot
Molecular Anti-inflammatory Mechanisms of Retinoids and Carotenoids in Alzheimer’s Disease: a Review of Current Evidence
inferred← citeshttps://doi.org/10.1007/s12035-015-9249-4openalex-snapshot
Novel Sites of Neuroprotective Action of Dimebon (Latrepirdine)
inferred← citeshttps://doi.org/10.1007/s12035-020-01964-9openalex-snapshot
The Brain AT2R—a Potential Target for Therapy in Alzheimer’s Disease and Vascular Cognitive Impairment: a Comprehensive Review of Clinical and Experimental Therapeutics
inferred← citeshttps://doi.org/10.1007/s12035-021-02350-9openalex-snapshot
Verapamil Prevents Development of Cognitive Impairment in an Aged Mouse Model of Sporadic Alzheimer’s Disease
inferred← citeshttps://doi.org/10.1007/s12975-022-01000-zopenalex-snapshot
Recycled Translation: Repurposing Drugs for Stroke
inferred← citeshttps://doi.org/10.1007/s13311-014-0325-7openalex-snapshot
Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer's Disease
inferred← citeshttps://doi.org/10.1016/b978-0-12-818697-8.00108-4openalex-snapshot
Dementia
inferred← citeshttps://doi.org/10.1016/b978-0-443-18677-6.00010-5openalex-snapshot
Repositioning of receptor tyrosine kinase inhibitors
inferred← citeshttps://doi.org/10.1016/b978-3-437-24905-1.16001-0openalex-snapshot
Literaturverzeichnis zu Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkankungen, 9. Auflage
inferred← citeshttps://doi.org/10.1016/b978-3-437-24906-8.16001-6openalex-snapshot
Literaturverzeichnis zu Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 10. Auflage
inferred← citeshttps://doi.org/10.1016/j.arr.2025.103001openalex-snapshot
Targeting brain connectivity in Alzheimer’s disease with repurposed drugs
inferred← citeshttps://doi.org/10.1016/j.bbi.2022.10.009openalex-snapshot
Prevention of microgliosis halts early memory loss in a mouse model of Alzheimer’s disease
inferred← citeshttps://doi.org/10.1016/j.bcp.2012.11.014openalex-snapshot
Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond?
inferred← citeshttps://doi.org/10.1016/j.bioactmat.2023.10.025openalex-snapshot
DNA tetrahedral nanostructures for the biomedical application and spatial orientation of biomolecules
inferred← citeshttps://doi.org/10.1016/j.biomaterials.2018.12.027openalex-snapshot
Progressive release of mesoporous nano-selenium delivery system for the multi-channel synergistic treatment of Alzheimer's disease
inferred← citeshttps://doi.org/10.1016/j.bmc.2021.116091openalex-snapshot
Investigations on substituted (2-aminothiazol-5-yl)(imidazo[1,2-a]pyridin-3-yl)methanones for the treatment of Alzheimer’s disease
inferred← citeshttps://doi.org/10.1016/j.bmcl.2015.02.015openalex-snapshot
Design, synthesis and evaluation of novel 5,6,7-trimethoxyflavone–6-chlorotacrine hybrids as potential multifunctional agents for the treatment of Alzheimer’s disease
inferred← citeshttps://doi.org/10.1016/j.bmcl.2017.09.051openalex-snapshot
Flavonoids and their derivatives with β-amyloid aggregation inhibitory activity from the leaves and twigs of Pithecellobium clypearia Benth
inferred← citeshttps://doi.org/10.1016/j.bmcl.2018.09.031openalex-snapshot
Identification of steroidal derivatives inhibiting the transformations of allopregnanolone and estradiol by 17β-hydroxysteroid dehydrogenase type 10
inferred← citeshttps://doi.org/10.1016/j.brainres.2015.05.035openalex-snapshot
Paeoniflorin attenuates Aβ1-42-induced inflammation and chemotaxis of microglia in vitro and inhibits NF-κB- and VEGF/Flt-1 signaling pathways
inferred← citeshttps://doi.org/10.1016/j.brainres.2022.147786openalex-snapshot
Polysorbate-coated mesoporous silica nanoparticles as an efficient carrier for improved rivastigmine brain delivery
inferred← citeshttps://doi.org/10.1016/j.brainresbull.2014.11.003openalex-snapshot
Medical genetics-based drug repurposing for Alzheimer's disease
inferred← citeshttps://doi.org/10.1016/j.btre.2025.e00909openalex-snapshot
Prioritizing repurposable drugs for Alzheimer’s disease using network-based analysis with concurrent assessment of Long QT syndrome risk
inferred← citeshttps://doi.org/10.1016/j.cclet.2020.03.028openalex-snapshot
New techniques and strategies in drug discovery
inferred← citeshttps://doi.org/10.1016/j.clinph.2013.10.015openalex-snapshot
Global complexity and cognitive reserve in MCI
inferred← citeshttps://doi.org/10.1016/j.compbiolchem.2025.108378openalex-snapshot
Repurposing of dipeptidyl peptidase FDA-approved drugs in Alzheimer’s disease using network pharmacology and in-silico approaches
inferred← citeshttps://doi.org/10.1016/j.crphar.2021.100022openalex-snapshot
Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders
inferred← citeshttps://doi.org/10.1016/j.csbj.2021.08.003openalex-snapshot
A data-driven methodology towards evaluating the potential of drug repurposing hypotheses
inferred← citeshttps://doi.org/10.1016/j.ejmech.2022.114239openalex-snapshot
Drug repositioning: Progress and challenges in drug discovery for various diseases
inferred← citeshttps://doi.org/10.1016/j.ejps.2014.09.014openalex-snapshot
Repositioning of 2,4-Dichlorophenoxy acetic acid as a potential anti-inflammatory agent: In Silico and Pharmaceutical Formulation study
inferred← citeshttps://doi.org/10.1016/j.envres.2021.111320openalex-snapshot
In-vitro evaluation of antioxidant and anticholinesterase activities of novel pyridine, quinoxaline and s-triazine derivatives
inferred← citeshttps://doi.org/10.1016/j.healthpol.2013.07.023openalex-snapshot
Health care for people with dementia in 2030 – Results of a multidisciplinary scenario process
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2025.143300openalex-snapshot
Intranasal resveratrol delivery to the brain with chitosan-decorated bovine serum albumin nanoparticles: Advancing Alzheimer's management in old female rats through QbD-based optimization, in vitro evaluation, and in vivo exploration
inferred← citeshttps://doi.org/10.1016/j.isci.2022.104052openalex-snapshot
PharmOmics: A species- and tissue-specific drug signature database and gene-network-based drug repositioning tool
inferred← citeshttps://doi.org/10.1016/j.jacbts.2016.11.010openalex-snapshot
Enabling Precision Cardiology Through Multiscale Biology and Systems Medicine
inferred← citeshttps://doi.org/10.1016/j.jalz.2013.12.004openalex-snapshot
How does brain insulin resistance develop in Alzheimer's disease?
inferred← citeshttps://doi.org/10.1016/j.jalz.2013.12.007openalex-snapshot
The nature, significance, and glucagon‐like peptide‐1 analog treatment of brain insulin resistance in Alzheimer's disease
inferred← citeshttps://doi.org/10.1016/j.jalz.2014.08.103openalex-snapshot
2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease
inferred← citeshttps://doi.org/10.1016/j.jconrel.2026.114896openalex-snapshot
Engineered microglial membrane-coated polydopamine-based nanomedicine for precise treatment of Alzheimer's disease
inferred← citeshttps://doi.org/10.1016/j.jff.2017.12.016openalex-snapshot
EPA enriched ethanolamine plasmalogens significantly improve cognition of Alzheimer’s disease mouse model by suppressing β-amyloid generation
inferred← citeshttps://doi.org/10.1016/j.jmgm.2021.107844openalex-snapshot
Drug design of new 5-HT6R antagonists aided by artificial neural networks
inferred← citeshttps://doi.org/10.1016/j.jneuroim.2016.10.004openalex-snapshot
All-trans retinoic acid (ATRA) prevents lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment in aged rats
inferred← citeshttps://doi.org/10.1016/j.jnrt.2022.100002openalex-snapshot
Acetylcholine bidirectionally regulates learning and memory
inferred← citeshttps://doi.org/10.1016/j.jpba.2016.11.013openalex-snapshot
LC–ESI–MS/MS evaluation of forced degradation behaviour of silodosin: In vitro anti cancer activity evaluation of silodosin and major degradation products
inferred← citeshttps://doi.org/10.1016/j.jpba.2023.115765openalex-snapshot
Spectrum-effect relationship analysis based on HPLC-FT-ICR-MS and multivariate statistical analysis to reveal the pharmacodynamic substances of Ling-Gui-Zhu-Gan decoction on Alzheimer's disease
inferred← citeshttps://doi.org/10.1016/j.lfs.2021.120267openalex-snapshot
Potential role of Drug Repositioning Strategy (DRS) for management of tauopathy
inferred← citeshttps://doi.org/10.1016/j.lungcan.2022.11.015openalex-snapshot
A novel cell-based assay for the high-throughput screening of epithelial–mesenchymal transition inhibitors: Identification of approved and investigational drugs that inhibit epithelial–mesenchymal transition
inferred← citeshttps://doi.org/10.1016/j.maturitas.2013.04.013openalex-snapshot
Drug development in dementia
inferred← citeshttps://doi.org/10.1016/j.mcn.2021.103612openalex-snapshot
Inhibitory mechanism of an antifungal drug, caspofungin against amyloid β peptide aggregation: Repurposing via neuroinformatics and an experimental approach
inferred← citeshttps://doi.org/10.1016/j.neuint.2016.04.012openalex-snapshot
Plasma soluble neuregulin-1 as a diagnostic biomarker for Alzheimer's disease
inferred← citeshttps://doi.org/10.1016/j.neurobiolaging.2017.05.014openalex-snapshot
Cholinergic neuron gene expression differences captured by translational profiling in a mouse model of Alzheimer's disease
inferred← citeshttps://doi.org/10.1016/j.neuropharm.2020.108081openalex-snapshot
Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery
inferred← citeshttps://doi.org/10.1016/j.neuroscience.2025.08.055openalex-snapshot
Integrating artificial intelligence with small molecule therapeutics and precision medicine for neurochemical understanding of Alzheimer’s diseases
inferred← citeshttps://doi.org/10.1016/j.npg.2024.02.002openalex-snapshot
Les effets positifs et négatifs du microbiote sur le développement de la démence et le rôle de la transplantation fécale
inferred← citeshttps://doi.org/10.1016/j.pbb.2014.02.016openalex-snapshot
Retinoids as potential targets for Alzheimer's disease
inferred← citeshttps://doi.org/10.1016/j.phrs.2017.11.021openalex-snapshot
Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention
inferred← citeshttps://doi.org/10.1016/j.tibtech.2017.06.002openalex-snapshot
Advances in Alzheimer’s Diagnosis and Therapy: The Implications of Nanotechnology
inferred← citeshttps://doi.org/10.1016/j.tips.2019.06.003openalex-snapshot
Insights into Computational Drug Repurposing for Neurodegenerative Disease
inferred← citeshttps://doi.org/10.1016/j.tjpad.2025.100329openalex-snapshot
Identifying synergistic combinations of repurposed treatments for Alzheimer’s Disease
inferred← citeshttps://doi.org/10.1016/j.trci.2016.10.001openalex-snapshot
A multicenter, randomized, placebo‐controlled trial for cilostazol in patients with mild cognitive impairment: The COMCID study protocol
inferred← citeshttps://doi.org/10.1017/9781108975759.006openalex-snapshot
Repurposed Agents in Alzheimer’s Disease Drug Development
inferred← citeshttps://doi.org/10.1021/acs.inorgchem.6b00525openalex-snapshot
Importance of the Dimethylamino Functionality on a Multifunctional Framework for Regulating Metals, Amyloid-β, and Oxidative Stress in Alzheimer’s Disease
inferred← citeshttps://doi.org/10.1021/acs.jafc.1c03247openalex-snapshot
Characterization of Metabolites in a Zebrafish Model of Alzheimer’s Disease Supplemented with Mussel-Derived Plasmalogens by Ultraperformance Liquid Chromatography Q-Exactive Orbitrap Mass Spectrometry-Based Unbiased Metabolomics
inferred← citeshttps://doi.org/10.1021/acs.jcim.7b00225openalex-snapshot
IFPTarget: A Customized Virtual Target Identification Method Based on Protein–Ligand Interaction Fingerprinting Analyses
inferred← citeshttps://doi.org/10.1021/acs.jcim.9b00821openalex-snapshot
Identification of Target Associations for Polypharmacology from Analysis of Crystallographic Ligands of the Protein Data Bank
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.2c00335openalex-snapshot
Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer’s Disease
inferred← citeshttps://doi.org/10.1021/acs.molpharmaceut.8b00041openalex-snapshot
New Flavone-Cyanoacetamide Hybrids with a Combination of Cholinergic, Antioxidant, Modulation of β-Amyloid Aggregation, and Neuroprotection Properties as Innovative Multifunctional Therapeutic Candidates for Alzheimer’s Disease and Unraveling Their Mechanism of Action with Acetylcholinesterase
inferred← citeshttps://doi.org/10.1021/acschemneuro.0c00414openalex-snapshot
Gabapentin Inhibits Multiple Steps in the Amyloid Beta Toxicity Cascade
inferred← citeshttps://doi.org/10.1021/acschemneuro.4c00150openalex-snapshot
Repurposing Anidulafungin for Alzheimer’s Disease via Fragment-Based Drug Discovery
inferred← citeshttps://doi.org/10.1021/acschemneuro.8b00160openalex-snapshot
Interactions of Selective Serotonin Reuptake Inhibitors with β-Amyloid
inferred← citeshttps://doi.org/10.1021/acsomega.2c06634openalex-snapshot
Linagliptin and Empagliflozin Inhibit Microtubule Affinity Regulatory Kinase 4: Repurposing Anti-Diabetic Drugs in Neurodegenerative Disorders Using In Silico and In Vitro Approaches
inferred← citeshttps://doi.org/10.1021/acsomega.9b02160openalex-snapshot
Fingerprinting CANDO: Increased Accuracy with Structure- and Ligand-Based Shotgun Drug Repurposing
inferred← citeshttps://doi.org/10.1021/ja409801popenalex-snapshot
Rational Design of a Structural Framework with Potential Use to Develop Chemical Reagents That Target and Modulate Multiple Facets of Alzheimer’s Disease
inferred← citeshttps://doi.org/10.1021/jm400658eopenalex-snapshot
Dipeptidyl Peptidase IV and Its Inhibitors: Therapeutics for Type 2 Diabetes and What Else?
inferred← citeshttps://doi.org/10.1021/ml500065qopenalex-snapshot
Synthesis of [11C]Bexarotene by Cu-Mediated [11C]Carbon Dioxide Fixation and Preliminary PET Imaging
inferred← citeshttps://doi.org/10.1021/mp300570zopenalex-snapshot
Confounding Parameters in Preclinical Assessment of Blood–Brain Barrier Permeation: An Overview With Emphasis on Species Differences and Effect of Disease States
inferred← citeshttps://doi.org/10.1038/mp.2013.20openalex-snapshot
The vascular depression hypothesis: mechanisms linking vascular disease with depression
inferred← citeshttps://doi.org/10.1038/nrd.2018.21openalex-snapshot
Kinase inhibitors: the road ahead
inferred← citeshttps://doi.org/10.1038/s41392-020-00311-7openalex-snapshot
NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential
inferred← citeshttps://doi.org/10.1038/s41416-019-0609-0openalex-snapshot
Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies
inferred← citeshttps://doi.org/10.1038/s41421-021-00363-1openalex-snapshot
Targeting macrophage TFEB-14-3-3 epsilon Interface by naringenin inhibits abdominal aortic aneurysm
inferred← citeshttps://doi.org/10.1038/s41467-021-21330-0openalex-snapshot
Machine learning identifies candidates for drug repurposing in Alzheimer’s disease
inferred← citeshttps://doi.org/10.1038/s41537-025-00664-4openalex-snapshot
Association between antidiabetic drug targets and psychiatric disorders
inferred← citeshttps://doi.org/10.1038/s41573-019-0036-1openalex-snapshot
Lysosomes as a therapeutic target
inferred← citeshttps://doi.org/10.1038/s41582-020-0397-4openalex-snapshot
Drug repositioning and repurposing for Alzheimer disease
inferred← citeshttps://doi.org/10.1038/s41598-018-27395-0openalex-snapshot
Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent
inferred← citeshttps://doi.org/10.1038/s41598-022-10133-yopenalex-snapshot
Novel use of FDA-approved drugs identified by cluster analysis of behavioral profiles
inferred← citeshttps://doi.org/10.1038/s41598-025-85947-7openalex-snapshot
DeepDrug as an expert guided and AI driven drug repurposing methodology for selecting the lead combination of drugs for Alzheimer’s disease
inferred← citeshttps://doi.org/10.1038/s43856-024-00638-0openalex-snapshot
Impact of commonly administered drugs on the progression of spinal cord injury: a systematic review
inferred← citeshttps://doi.org/10.1038/srep16541openalex-snapshot
The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer’s disease amyloid-β peptides
inferred← citeshttps://doi.org/10.1038/srep23372openalex-snapshot
Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin polymerization
inferred← citeshttps://doi.org/10.1038/tp.2014.61openalex-snapshot
Plasma DYRK1A as a novel risk factor for Alzheimer’s disease
inferred← citeshttps://doi.org/10.1038/tp.2015.87openalex-snapshot
Modifications of the endosomal compartment in peripheral blood mononuclear cells and fibroblasts from Alzheimer’s disease patients
inferred← citeshttps://doi.org/10.1039/c4ra11856aopenalex-snapshot
An α 1 -adrenergic receptor ligand repurposed as a potent antiproliferative agent for head and neck squamous cell carcinoma
inferred← citeshttps://doi.org/10.1039/c4sc03239jopenalex-snapshot
A rationally designed small molecule for identifying an in vivo link between metal–amyloid-β complexes and the pathogenesis of Alzheimer's disease
inferred← citeshttps://doi.org/10.1039/c4sc03416copenalex-snapshot
Computational discovery and experimental verification of tyrosine kinase inhibitor pazopanib for the reversal of memory and cognitive deficits in rat model neurodegeneration
inferred← citeshttps://doi.org/10.1039/c5ob01478fopenalex-snapshot
Effects of structural modifications on the metal binding, anti-amyloid activity, and cholinesterase inhibitory activity of chalcones
inferred← citeshttps://doi.org/10.1039/c5ra26424copenalex-snapshot
Anti-choline esterase activity of ceramides from the Red Sea marine sponge Mycale euplectellioides
inferred← citeshttps://doi.org/10.1039/d0bm00756kopenalex-snapshot
Multifunctional nano-enabled delivery systems in Alzheimer's disease management
inferred← citeshttps://doi.org/10.1073/pnas.1422998112openalex-snapshot
Edaravone alleviates Alzheimer’s disease-type pathologies and cognitive deficits
inferred← citeshttps://doi.org/10.1080/07391102.2023.2252116openalex-snapshot
Computational Prediction of 3,5-Diaryl-1H-Pyrazole and spiropyrazolines derivatives as potential acetylcholinesterase inhibitors for alzheimer disease treatment by 3D-QSAR, molecular docking, molecular dynamics simulation, and ADME-Tox
inferred← citeshttps://doi.org/10.1080/14656566.2016.1258060openalex-snapshot
Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer’s disease
inferred← citeshttps://doi.org/10.1080/14737175.2017.1326818openalex-snapshot
Emerging treatments for Alzheimer’s disease for non-amyloid and non-tau targets
inferred← citeshttps://doi.org/10.1080/14737175.2017.1326819openalex-snapshot
Emerging amyloid and tau targeting treatments for Alzheimer’s disease
inferred← citeshttps://doi.org/10.1080/14737175.2019.1608823openalex-snapshot
Non-conventional compounds with potential therapeutic effects against Alzheimer’s disease
inferred← citeshttps://doi.org/10.1080/14737175.2020.1708195openalex-snapshot
Antihypertensive agents in Alzheimer’s disease: beyond vascular protection
inferred← citeshttps://doi.org/10.1088/1361-6633/ac3800openalex-snapshot
Physics of biomolecular recognition and conformational dynamics
inferred← citeshttps://doi.org/10.1093/bioinformatics/btz600openalex-snapshot
Discovering protein drug targets using knowledge graph embeddings
inferred← citeshttps://doi.org/10.1093/brain/awaa115openalex-snapshot
Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation
inferred← citeshttps://doi.org/10.1093/cvr/cvac110openalex-snapshot
Antihypertensive drugs and brain function: mechanisms underlying therapeutically beneficial and harmful neuropsychiatric effects
inferred← citeshttps://doi.org/10.1093/gerona/glab376openalex-snapshot
Higher Angiotensin II Type 1 Receptor Levels and Activity in the Postmortem Brains of Older Persons with Alzheimer’s Dementia
inferred← citeshttps://doi.org/10.1093/ije/dyx207openalex-snapshot
Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities
inferred← citeshttps://doi.org/10.1093/ije/dyz155openalex-snapshot
Repurposing antihypertensive drugs for the prevention of Alzheimer’s disease: a Mendelian randomization study
inferred← citeshttps://doi.org/10.1093/jamiaopen/ooag060openalex-snapshot
Feasibility of identifying factors related to Alzheimer’s disease and related dementia in real-world data
inferred← citeshttps://doi.org/10.1093/nar/gkt401openalex-snapshot
VisANT 4.0: Integrative network platform to connect genes, drugs, diseases and therapies
inferred← citeshttps://doi.org/10.1093/qjmed/hcu072openalex-snapshot
Can we reduce the risk of dementia?: Table 1
inferred← citeshttps://doi.org/10.1096/fj.201901984ropenalex-snapshot
BHBA treatment improves cognitive function by targeting pleiotropic mechanisms in transgenic mouse model of Alzheimer's disease
inferred← citeshttps://doi.org/10.1096/fj.202001271ropenalex-snapshot
Selective loss of 5hmC promotes neurodegeneration in the mouse model of Alzheimer's disease
inferred← citeshttps://doi.org/10.1097/ede.0000000000001245openalex-snapshot
Comparison of Antihypertensive Drug Classes for Dementia Prevention
inferred← citeshttps://doi.org/10.1101/2020.07.12.199398openalex-snapshot
Crowdsourcing Machine Intelligence Solutions to Accelerate Biomedical Science: Lessons learned from a machine intelligence ideation contest to improve the prediction of 3D domain swapping
inferred← citeshttps://doi.org/10.1101/2023.09.15.557737openalex-snapshot
Transcriptomic signatures of Aβ- and tau-induced neuronal dysfunction reveal inflammatory processes at the core of Alzheimer’s disease pathophysiology
inferred← citeshttps://doi.org/10.1101/2024.07.06.24309990openalex-snapshot
DeepDrug: An Expert-led Domain-specific AI-Driven Drug-Repurposing Mechanism for Selecting the Lead Combination of Drugs for Alzheimer’s Disease
inferred← citeshttps://doi.org/10.1101/2024.09.12.24313578openalex-snapshot
Non-pharmacological interventions for psychotic symptoms in people with dementia: a Delphi consensus
inferred← citeshttps://doi.org/10.1101/2025.03.09.25323612openalex-snapshot
Systematic Living Evidence for Clinical Trials (SyLECT): a data-driven framework for drug selection in clinical trials in motor neuron disease
inferred← citeshttps://doi.org/10.1101/622308openalex-snapshot
Identifying Novel Candidates for Re-Purposing as Potential Therapeutic Agents for Alzheimer’s disease
inferred← citeshttps://doi.org/10.1101/837773openalex-snapshot
PharmOmics: A Species- and Tissue-specific Drug Signature Database and Online Tool for Drug Repurposing
inferred← citeshttps://doi.org/10.1108/lht-08-2019-0170openalex-snapshot
Drug repurposing against Parkinson's disease by text mining the scientific literature
inferred← citeshttps://doi.org/10.1109/ichi.2019.8904505openalex-snapshot
Systematic Design of Drug Repurposing-Oriented Alzheimer’s Disease Ontology
inferred← citeshttps://doi.org/10.1111/jnc.14256openalex-snapshot
Shared pathological pathways of Alzheimer's disease with specific comorbidities: current perspectives and interventions
inferred← citeshttps://doi.org/10.1111/pcn.13892openalex-snapshot
Repurposed antihypertensive drugs for negative symptoms in schizophrenia: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1126/scitranslmed.aac9888openalex-snapshot
Data gaps limit the translational potential of preclinical research
inferred← citeshttps://doi.org/10.1136/bmjopen-2016-012044openalex-snapshot
Can commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimer's and other neurodegenerative diseases? Protocol for an observational cohort study in the UK Clinical Practice Research Datalink
inferred← citeshttps://doi.org/10.1136/bmjopen-2016-012177openalex-snapshot
Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank
inferred← citeshttps://doi.org/10.1136/jnnp-2020-324286openalex-snapshot
Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis
inferred← citeshttps://doi.org/10.1142/s0192415x19500757openalex-snapshot
Puerariae Radix Prevents Anxiety and Cognitive Deficits in Mice Under Oligomeric Aβ-Induced Stress
inferred← citeshttps://doi.org/10.1145/3297280.3297282openalex-snapshot
Drug target discovery using knowledge graph embeddings
inferred← citeshttps://doi.org/10.1155/2021/6694698openalex-snapshot
A Study to Decipher the Potential Effects of Butylphthalide against Central Nervous System Diseases Based on Network Pharmacology and Molecular Docking Integration Strategy
inferred← citeshttps://doi.org/10.1155/2021/9918498openalex-snapshot
Integrated Analysis of Weighted Gene Coexpression Network Analysis Identifying Six Genes as Novel Biomarkers for Alzheimer’s Disease
inferred← citeshttps://doi.org/10.1155/2022/3698518openalex-snapshot
The Study of Steaming Durations and Temperatures on the Chemical Characterization, Neuroprotective, and Antioxidant Activities of Panax notoginseng
inferred← citeshttps://doi.org/10.1159/000541783openalex-snapshot
Anti-Amyloid Drugs for Alzheimer’s Disease: Considering the Role of Depression
inferred← citeshttps://doi.org/10.1177/0271678x15606721openalex-snapshot
A novel mechanism of neuroprotection: Blood glutamate grabber
inferred← citeshttps://doi.org/10.1177/1087057114563024openalex-snapshot
In Vitro Screening for Drug Repositioning
inferred← citeshttps://doi.org/10.1177/13872877251319054openalex-snapshot
Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1186/1741-7015-11-82openalex-snapshot
Potential repurposing of oncology drugs for the treatment of Alzheimer's disease
inferred← citeshttps://doi.org/10.1186/alzrt277openalex-snapshot
Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease
inferred← citeshttps://doi.org/10.1186/s12859-022-04773-0openalex-snapshot
Identification of pan-kinase-family inhibitors using graph convolutional networks to reveal family-sensitive pre-moieties
inferred← citeshttps://doi.org/10.1186/s12868-015-0208-9openalex-snapshot
Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia
inferred← citeshttps://doi.org/10.1186/s12868-017-0394-8openalex-snapshot
In silico repurposing of antipsychotic drugs for Alzheimer’s disease
inferred← citeshttps://doi.org/10.1186/s13024-015-0046-3openalex-snapshot
Ethosuximide ameliorates neurodegenerative disease phenotypes by modulating DAF-16/FOXO target gene expression
inferred← citeshttps://doi.org/10.1186/s13040-025-00466-5openalex-snapshot
Drug repurposing for Alzheimer’s disease using a graph-of-thoughts based large language model to infer drug-disease relationships in a comprehensive knowledge graph
inferred← citeshttps://doi.org/10.1186/s13041-016-0272-9openalex-snapshot
Insight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profiling
inferred← citeshttps://doi.org/10.1186/s13195-018-0457-9openalex-snapshot
Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials
inferred← citeshttps://doi.org/10.1186/s13195-022-01103-7openalex-snapshot
RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus
inferred← citeshttps://doi.org/10.1186/s13195-025-01706-wopenalex-snapshot
Beyond expectations: investigating nilotinib’s potential in attenuating neurodegeneration in Alzheimer’s disease
inferred← citeshttps://doi.org/10.1186/s13195-025-01895-4openalex-snapshot
Drug repurposing for Alzheimer’s disease: a Delphi consensus and stakeholder consultation
inferred← citeshttps://doi.org/10.1186/s43094-026-00963-2openalex-snapshot
Exploring the potential of SGLT2 inhibitors in Alzheimer’s disease: network pharmacology, molecular docking, and MD simulation study
inferred← citeshttps://doi.org/10.1212/wnl.0000000000200771openalex-snapshot
Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer Disease Risk
inferred← citeshttps://doi.org/10.1242/dmm.018218openalex-snapshot
Triptolide treatment reduces Alzheimer’s disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD
inferred← citeshttps://doi.org/10.12688/f1000research.157890.1openalex-snapshot
Developing treatments for cerebral small vessel disease: a scoping review of licensed interventions for potential repurposing
inferred← citeshttps://doi.org/10.1371/journal.pone.0105196openalex-snapshot
Molecular Investigations of Protriptyline as a Multi-Target Directed Ligand in Alzheimer's Disease
inferred← citeshttps://doi.org/10.1371/journal.pone.0109438openalex-snapshot
Effects of Secondary Metabolite Extract from Phomopsis occulta on β-Amyloid Aggregation
inferred← citeshttps://doi.org/10.1371/journal.pone.0111668openalex-snapshot
A Network-Based Classification Model for Deriving Novel Drug-Disease Associations and Assessing Their Molecular Actions
inferred← citeshttps://doi.org/10.1371/journal.pone.0129370openalex-snapshot
Checking the STEP-Associated Trafficking and Internalization of Glutamate Receptors for Reduced Cognitive Deficits: A Machine Learning Approach-Based Cheminformatics Study and Its Application for Drug Repurposing
inferred← citeshttps://doi.org/10.1371/journal.pone.0177743openalex-snapshot
DrugSig: A resource for computational drug repositioning utilizing gene expression signatures
inferred← citeshttps://doi.org/10.14748/ssp.v6i2.6734openalex-snapshot
FT-IR spectral analysis for a newly obtained structure analog of bexarotene
showing the first 200 of 295 · page through all 295
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.